| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[18] Dolutegravir, oral (risk acknowledgement): National Department of Health. Circular no.1 of 2020: Introduction of Dolutegravir in the ARV Programme, 24 February 2020. http://www.health.gov.za